Clinical Significance of DPYD Gene Polymorphism Testing in Colorectal Cancer Patients Receiving Fluoropyrimidine-Based Chemotherapy: A Single-Center Study in Latvia European Scientific Journal ESJ

https://www.academia.edu/172721931/Clinical_Significance_of_DPYD_Gene_Polymorphism_Testing_in_Colorectal_Cancer_Patients_Receiving_Fluoropyrimidine_Based_Chemotherapy_A_Single_Center_Study_in_Latvia Background: Fluoropyrimidine-based chemotherapy, including 5fluorouracil (5-FU) and capecitabine, is a cornerstone of colorectal cancer (CRC) treatment. However, treatment-related toxicity varies substantially among patients and is influenced by pharmacogenetic factors. Variants in the DPYD gene, which encodes the enzyme dihydropyrimidine dehydrogenase (DPD), are associated with reduced enzyme activity and an increased risk of severe toxicity. Aim: To evaluate the prevalence of clinically relevant DPYD polymorphisms in Latvian CRC patients receiving fluoropyrimidine-based chemotherapy and assess the clinical impact of genotype-guided dose adjustment. Methods: This single-center observational study included 46 patients with histologically confirmed CRC treated at Pauls Stradiņš Clinical University Hospital. Patients were divided into retrospective and prospective cohorts. Genotyping was performed for four clinically relevant DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T, and c.1236G>A). Clinical data, treatment modifications, and toxicity outcomes were analyzed. Toxicity was graded according to CTCAE criteria. Descriptive statistics and Pearson's chisquare test were used for statistical analysis.

Shaping the Future of Precision Oncology: Biomarker-Driven Care for Tumor-Agnostic Therapies Authors: Benedikt Westphalen, MD, PhD; Vivek Subbiah, MD

https://www.medscape.org/viewarticle/shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk?page=1&src=mkmcmr_driv_stan_mscpedu_260901-OUS-HONC-shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk-cta&uac=148436CN